United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Andrew Hill Investment Advisors Inc.

Andrew Hill Investment Advisors Inc. grew its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 79.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 13,634 shares of the biotechnology company's stock after acquiring an additional 6,044 shares during the period. United Therapeutics comprises 3.6% of Andrew Hill Investment Advisors Inc.'s investment portfolio, making the stock its 13th biggest holding. Andrew Hill Investment Advisors Inc.'s holdings in United Therapeutics were worth $4,811,000 as of its most recent filing with the SEC.

• Liquidia: Court victory the awakening of an industry giant?

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Milestone Asset Management LLC lifted its position in United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock worth $1,014,000 after acquiring an additional 1,037 shares during the period. Korea Investment CORP raised its holdings in shares of United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after purchasing an additional 2,300 shares during the period. Janney Montgomery Scott LLC raised its position in United Therapeutics by 9.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock valued at $3,326,000 after purchasing an additional 789 shares during the period. JPMorgan Chase & Co. grew its stake in United Therapeutics by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company's stock valued at $68,999,000 after purchasing an additional 50,291 shares in the last quarter. Finally, Burney Co. raised its stake in United Therapeutics by 113.3% during the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company's stock valued at $8,441,000 after buying an additional 12,705 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on UTHR shares. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $388.25.

• Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Read Our Latest Stock Report on UTHR

United Therapeutics Stock Up 4.7 %

Shares of United Therapeutics stock opened at $292.78 on Thursday. The business has a fifty day simple moving average of $326.18 and a 200-day simple moving average of $352.23. United Therapeutics Co. has a fifty-two week low of $230.39 and a fifty-two week high of $417.82. The firm has a market cap of $13.15 billion, a price-to-earnings ratio of 12.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the company posted $4.36 EPS. Analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In related news, Director Raymond Dwek sold 4,000 shares of the firm's stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the transaction, the director now directly owns 1,750 shares of the company's stock, valued at $497,962.50. This trade represents a 69.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $940,373.07. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 87,500 shares of company stock valued at $30,640,680. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Stories

• Five stocks we like better than United Therapeutics
• High Dividend REITs: Are They an Ideal Way to Diversify?
• Broadcom's Big Outperformance Shows Strength Amid Tariff Decline
• What Are Dividend Challengers?
• Carvana: Can Turnaround Strength Outdrive Market Headwinds?
• What Investors Must Know About Over-the-Counter (OTC) Stocks
• Meta Seeks Trump's Help in FTC Trial: The Implications Are Huge

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in United Therapeutics Right Now?

Before you consider United Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.

While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here